The True Cost of STI Testing: Understanding Cost Per Reportable Result

Why "Cost Per Test" Is a Misleading Metric

When a lab quotes you $18 per NAAT test, it sounds straightforward. You run 300 tests a month, you pay $5,400. Simple.

Except that's not what actually happens. In reality, a meaningful percentage of those 300 tests will never produce a billable, clinically actionable result. Specimens get rejected. Samples fail QC. Redraws get ordered. Controls and calibrators consume reagents. Administrative handling generates overhead that doesn't appear on the line item but absolutely appears in your budget.

Cost per reportable result (CPRR) captures all of that. It's the total dollars spent — reagents, labor, overhead, failed runs, and retests — divided only by the tests that actually generated a final result a clinician could act on.

That distinction matters enormously. A lab offering $18 per test with a 12% reject rate has a very different true cost than a lab offering $22 per test with a 1.5% reject rate. On a 300-test month, the cheaper lab may actually cost you more — and deliver fewer results to patients.

What Is a "Reportable Result"?

A reportable result is a finalized, clinically actionable test outcome that can be delivered to an ordering provider. It's the end product — the thing that actually matters for patient care.

A test that fails QC is not a reportable result. A specimen rejected for hemolysis is not a reportable result. A redraw that the patient doesn't return for is not a reportable result. You paid for those tests. You got nothing from them.

For STI NAAT testing specifically — CT/NG/TV panels — three categories of non-reportable outcomes consistently inflate true costs:

• Specimen rejection — Improper collection, incorrect transport media, temperature excursions, insufficient volume
• QC and calibrator runs — Required by CLIA-compliant labs; these consume reagents but produce no patient result
• Indeterminate or invalid results — Inhibition, equivocal PCR signal, platform errors requiring repeat testing

In a well-run, high-volume reference lab, these categories combined typically account for 3–8% of total test volume. In lower-throughput or poorly optimized operations, that number can exceed 15%.

Industry Benchmarks for STI NAAT Testing Costs

Understanding where your costs should land requires real market data. Here are current benchmarks for high-volume STI NAAT testing (CT/NG/TV) based on publicly available federal supply schedule pricing, FQHC network data, and urgent care chain contracting norms.

The gap between high-volume and low-volume CPRR is not primarily a negotiation story — it's a routing story. Clinics running 500+ tests/month against a single lab partner are leaving significant savings on the table compared to networks that actively route volume across 3–5 partners.

Hidden Costs That Inflate Your True Per-Test Cost

The invoice is the visible cost. The following cost drivers are largely invisible — but real.

1. Specimen Rejection and Redraw Overhead

When a specimen is rejected, the direct test cost is lost. But the indirect costs compound: staff time to notify the ordering provider, patient recall, a second collection visit, repeat transport, and another processing run. A single rejected specimen in an urgent care setting commonly represents $40–80 in total operational cost once staff time, patient no-shows, and the eventual retest are factored in.

A lab with a 5% reject rate on 1,000 monthly tests generates 50 rejected specimens. At $60 average fully-loaded redraw cost, that's $3,000/month in invisible overhead — none of which appears on your lab invoice.

2. Administrative and Billing Overhead

Labs using traditional per-CPT billing generate itemized invoices with multiple line items per order. Reconciling those against your EHR, disputing incorrect charges, and managing billing staff time costs healthcare organizations an estimated $12–18 per claim in administrative overhead (HFMA benchmark). For high-volume STI testing, this alone can exceed $5,000/month at a 300-test cadence.

CPRR-based contracts eliminate most of this by design. One price, one line item, one reconciliation.

3. Rush and Expedite Surcharges

Urgent care is, by definition, time-sensitive. Labs frequently charge 1.5–2× standard rates for rush processing. If your standard TAT is 3 days and clinical need demands next-day results, you're routinely paying premiums that don't appear in your base rate negotiation. Clinics that haven't explicitly negotiated TAT SLAs often pay rush fees 20–35% of the time without realizing it.

4. Reagent and Supply Chain Surcharges

Traditional per-test pricing often includes pass-through clauses for reagent cost increases. When supply chain pressures spike reagent costs — as they did significantly in 2020–2022 — those increases flow directly through to your invoice. CPRR contracts absorb that risk on the lab side, which is a meaningful form of price insurance.

5. TAT-Driven Patient Attrition

The most underquantified cost in STI testing is the revenue lost when patients don't return for results. In behavioral health and sexual health contexts, same-day or next-day results drive meaningfully higher treatment initiation rates. A 3-day TAT that causes 8% of positive patients to never receive treatment represents both a public health failure and a missed CPT-driven revenue cycle event.

Cost-Per-Test vs. Cost-Per-Reportable-Result: A Direct Comparison

Here's how the two metrics diverge in a real-world scenario.

Metric	Cost-Per-Test Model	Cost-Per-Reportable-Result Model
What you pay for	Every test processed, regardless of outcome	Only finalized, clinically actionable results
Reject rate impact	You pay for rejected specimens	Rejected specimens don't count
QC/calibrator costs	Absorbed in opaque reagent line items	Included in CPRR formula, fully transparent
Budget predictability	Variable; spikes with quality issues	Fixed per result; easy to forecast
Lab incentive alignment	Lab profits from redraws and retests	Lab incentivized to minimize rejects
Administrative complexity	Multi-line invoices, disputed charges	Single line item per result
Rush surcharge exposure	Frequent implicit upcharges	TAT SLAs built into contract
True cost visibility	Requires significant back-calculation	Self-evident from invoice

How Lab Routing Optimizes CPRR

For most clinics, the single biggest lever on CPRR isn't negotiating harder with one lab — it's routing specimens intelligently across multiple labs based on real-time capacity, performance, and pricing.

Routing Logic That Reduces Cost

When a specimen is collected at your clinic, several routing variables are simultaneously relevant:

• Current lab capacity — A lab at 90% capacity runs slower and rejects more. Routes away from congested labs lower your reject rate without renegotiating anything.
• Current TAT performance — Live TAT data (not contractual promises) tells you which lab will hit 24-hour turnaround today. Static contracts don't.
• Specimen-specific reject history — Some labs have consistently higher reject rates on specific specimen types (rectal vs. urethral, urine vs. swab). Routing that accounts for historical per-lab reject rates can cut your overall reject rate by 30–50%.
• CPRR by volume tier — Most labs tier pricing by volume. As your monthly send-outs to a specific lab approach a volume threshold, your per-result cost decreases. Intelligent routing tracks these thresholds in real time.

Multi-Lab Routing in Practice

A network routing 800 STI NAAT tests/month across three labs — allocating volume dynamically based on capacity, TAT, and reject history — typically achieves:

• 15–30% lower CPRR vs. single-lab contracting at equivalent volume
• Reject rate under 2% vs. 3–5% single-lab average
• TAT within 24 hours >92% of the time vs. 70–80% for single-lab
• Zero billing disputes when CPRR contracts are paired with routing

This is exactly what ClearLane does. Our routing engine runs the math in real time — capacity, TAT, reject history, and CPRR tier thresholds — to assign each specimen to the optimal lab at the moment it's ordered. You don't manage lab relationships. You just run your clinic.

Calculating Your Current CPRR

Before you can benchmark or negotiate, you need your number. Here's how to calculate it:

1. Pull 90 days of lab invoices — Include all line items: base tests, reagent charges, handling fees, rush surcharges, and any miscellaneous fees.
2. Add fully-loaded redraw costs — Estimate staff time for patient recall, second collection visits, and repeat transport. A conservative estimate is $40–60 per rejected specimen.
3. Count reportable results only — From your LIS or EHR, count finalized results delivered in that 90-day window. Exclude rejected specimens, QNS, and indeterminate results.
4. Divide total cost by reportable results — That's your CPRR. Compare to the benchmarks above.

What to Ask Your Lab About CPRR

If your current lab isn't pricing on a CPRR basis, you can still hold them accountable to the metric. Ask:

• "What is your current reject rate for CT/NG/TV NAAT on our specimen types?" — Any answer above 3% warrants renegotiation or routing diversification.
• "What percentage of our invoiced tests generated a final, reportable result in the last 90 days?" — If they can't answer this, that's information.
• "What SLA penalties apply if TAT exceeds [X] business days?" — "Best effort" TAT is not a contract. Demand numeric penalties.
• "How do your prices change at 250, 500, and 1,000 tests/month?" — Know your volume tiers before you route.

Key Takeaways

• Cost per test is the wrong benchmark. It ignores rejects, QC overhead, and administrative waste. CPRR is the number that actually tracks your budget.
• Hidden costs are large. Rejected specimens, billing overhead, rush surcharges, and TAT-driven attrition add 20–40% to the sticker price of a typical per-test contract.
• Industry CPRR benchmarks: $12–25 for high-volume clinics; $28–45 for low-volume. The gap is mostly routing, not negotiation.
• CPRR contracts align incentives. When labs are paid per reportable result, they're financially motivated to minimize rejects and deliver results fast.
• Routing is the lever. Dynamic, multi-lab routing based on real-time capacity, TAT, and reject history is how well-run networks hit the low end of the CPRR range consistently.

Next step: Ready to evaluate specific lab partners? Use our Lab Partner Evaluation Checklist to score and compare candidates on the metrics that drive CPRR.

Learn more: Our STI Lab Routing Guide covers the full framework for building a multi-lab sourcing strategy from scratch.

Speed matters too: Understand the TAT benchmarks and SLA frameworks that protect your patients and your revenue cycle — STI Testing Turnaround Time Guide.